Table 4 Clinicopathologic characteristics according to histologic subtypes
Characteristics | Endometrioid (n = 18, %) | Non-endometrioid (n = 14, %) | P-value |
|---|---|---|---|
Age at diagnosis, years | 0.354 | ||
Median (range) | 56 (43–77) | 57 (34–68) | |
Menopausal status | 0.960 | ||
Premenopause | 5 (27.8) | 4 (28.6) | |
Postmenopause | 13 (72.2) | 10 (71.4) | |
Grade | < 0.001 | ||
Low | 11 (61.1) | ||
High | 7 (38.9) | ||
Not applicable | 14 (100) | ||
FIGO stage | 0.788 | ||
IIIC | 2 (11.1) | 2 (14.3) | |
IVB | 16 (88.9) | 12 (85.7) | |
CA-125 at diagnosis, IU/ml | 0.417 | ||
Median (range) | 181.7 (12.2–3489.0) | 193.6 (8.6–1800.0) | |
CA-125 after NAC, IU/ml | 0.417 | ||
Median (range) | 17.3 (7.0–1490.0) | 25.8 (7.0–391.0) | |
NAC regimen | 0.232 | ||
Paclitaxel-carboplatin | 15 (83.3) | 10 (71.4) | |
Doxorubicin-cisplatin | 0 | 2 (14.3) | |
Paclitaxel-cisplatin-bevacizumab | 2 (11.1) | 0 | |
Ifosfamide-cisplatin | 1 (5.6) | 1 (7.1) | |
Etoposide-cisplatin | 0 | 1 (7.1) | |
Number of NAC cycles | 0.616 | ||
Median (range) | 6 (2–12) | 6 (2–12) | |
2–3 | 6 (33.3) | 5 (35.7) | |
4–6 | 7 (38.9) | 3 (21.4) | |
≥7 | 5 (27.8) | 6 (42.9) | |
Response to NAC | 0.982 | ||
CR | 1 (5.6) | 1 (7.1) | |
PR | 14 (77.8) | 10 (71.4) | |
SD | 2 (11.1) | 2 (14.3) | |
PD | 1 (5.6) | 1 (7.1) | |
Residual tumor after IDS | 0.158 | ||
No gross residual | 12 (66.7) | 11 (78.6) | |
< 1 cm | 6 (33.3) | 1 (7.1) | |
≥ 1 cm | 0 | 2 (14.3) |